Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive lymphoma with characteristic NFkB pathway disturbances and BCL-2/mTOR protein deregulation, leading to inhibited apoptosis.
• Current treatment strategies target these pathways, but monotherapy may be insufficient, necessitating combination approaches.

Purpose of the Study:

• To evaluate the efficacy of novel inhibitors targeting BCL-2, mTOR, and NFκB, alone and in combination, against DLBCL cell lines representing ABC and GCB subtypes.

Main Methods:

• In vitro studies utilized Riva (ABC subtype) and Toledo (GCB subtype) DLBCL cell lines.
• Three novel drugs were tested: AZD2014 (mTOR inhibitor), IMD-0354 (NFκB inhibitor), and ABT-199 (BCL-2 inhibitor).
• Drugs were administered as monotherapy, in pairs, and in a three-drug combination.

Main Results:

• In Riva cells, ABT-199 showed the strongest monotherapy effect. Combinations of AZD2014+ABT-199 and ABT-199+IMD0354 were similarly effective, with no added benefit from the three-drug combination.
• In Toledo cells, monotherapy showed no significant differences. The AZD2014+ABT-199 combination was most effective, and the three-drug combination did not enhance this effect.

Conclusions:

• BCL-2 and mTOR inhibitors show potential in DLBCL treatment, particularly in specific combinations.
• Further in vivo studies are required to validate these findings and assess the therapeutic potential of these drug combinations for ABC and GCB subtypes of DLBCL.